Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis
T. Duparc, F. Briand, C. Trenteseaux, J. Merian, G. Combes, S. Najib, T. Sulpice, L. O. Martinez
This study develops a 3-week dietary mouse model of NASH and shows liraglutide reduces hepatic steatosis and inflammation.
bioRxiv · May 17, 2019Pathology